Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02586805 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
A Phase 3 study, sponsored by Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 125
- Enrollment target
NCT02586805 is a Phase 3 study that has completed, run by Shire. The registered enrollment target is 125 participants.
The verdict
NCT02586805, a Phase 3 study, has completed, sponsored by Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 125 participants
- Enrollment target
Study Summary
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
Interventions
- DRUG Placebo
- DRUG DX-2930 - 300mg/2wk
- DRUG DX-2930 - 300mg/4wk
- DRUG DX-2930 - 150mg/4wk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2016-03-03 |
| Est. Completion | 2017-04-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02586805
The ClinicalTrials.gov registry entry for NCT02586805 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02586805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02586805 about?
NCT02586805 is a clinical study titled "Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE". This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.
What is the current status of trial NCT02586805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 125 participants. The study started on 2016-03-03. Estimated completion is 2017-04-13.
What interventions are being tested in trial NCT02586805?
The interventions under investigation include: Placebo (DRUG), DX-2930 - 300mg/2wk (DRUG), DX-2930 - 300mg/4wk (DRUG), DX-2930 - 150mg/4wk (DRUG).
Who is sponsoring clinical trial NCT02586805?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.